Novartis AG, founded in 1996 and headquartered in Basel, Switzerland, is a leading global healthcare company focused on providing innovative medicines and treatments to improve patients' lives. The company specializes in pharmaceuticals, eye care, and generics, with well-known products including the cancer treatment Gleevec and the heart failure drug Entresto.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| NOVNVX 0.25% 2025-05-13 CHFNovartis AG | Switzerland | 2025-05-13 | 0.250 | 0.00 |
| NOVNVX 0.63% 2029-11-13 CHFNovartis AG | Switzerland | 2029-11-13 | 0.625 | 0.41 |
| NOVNVX 1.05% 2035-05-11 CHFNovartis AG | Switzerland | 2035-05-11 | 1.050 | 0.91 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Novartis has been active in the bond market since the early 2000s, issuing multiple bonds to finance its research and acquire other companies. Notably, the company issued a €5 billion bond in 2020 to strengthen its balance sheet amid the pandemic, which demonstrated investor confidence with low yields compared to industry peers. As of October 2023, Novartis bonds typically yield around 1.5% to 2%, reflecting the company's strong credit rating and stable cash flow generation. Recent news includes plans for a new bond issuance to fund upcoming research initiatives, underscoring its ongoing commitment to innovation.